Report: Prenatal testing is primed for a boom

The demand for noninvasive prenatal tests will nearly triple over the next 6 years, according to market researchers, reaching $3.6 billion in 2019 as more and more diagnostics outfits contend for dominance. According to Transparency Market Research, the prenatal space will grow roughly 38% a year as physicians and patients warm up to the safety and efficacy of tests from the likes of Sequenom ($SQNM), Natera and Illumina's ($ILMN) Verinata Health. More

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.